# OnCo record myeloma-relapsed-refractory (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/myeloma-relapsed-refractory/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "myeloma-relapsed-refractory" ;
  schema:name "Relapsed or refractory multiple myeloma"@en ;
  schema:alternateName "RRMM"@en, "Relapsed myeloma"@en, "Triple-class refractory myeloma"@en, "Penta-refractory myeloma"@en ;
  schema:description "Myeloma almost always returns, and each return is harder to treat. Two kinds of immune therapy aimed at the BCMA protein on myeloma cells, CAR-T cells (KarMMa-3, CARTITUDE-4) and off-the-shelf bispecific antibodies (MajesTEC), now give deep remissions after other drugs fail, and a second target, GPRC5D, gives another option."@en ;
  schema:url <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Multiple_myeloma> ;
  schema:citation <https://en.wikipedia.org/wiki/Multiple_myeloma>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/celmods/>, <https://onco.cc/technologies/car-t-manufacturing-process/> ;
  onco:targets <https://onco.cc/targets/bcma/>, <https://onco.cc/targets/gprc5d/>, <https://onco.cc/targets/cd38/>, <https://onco.cc/targets/xpo1/>, <https://onco.cc/targets/cereblon/> ;
  onco:terms <https://onco.cc/terms/step-up-dosing/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/proteasome-inhibitor/>, <https://onco.cc/terms/imid/>, <https://onco.cc/terms/mrd-negativity-myeloma/> ;
  onco:pipeline <https://onco.cc/drugs/ciltacabtagene-autoleucel/>, <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/drugs/talquetamab/>, <https://onco.cc/drugs/linvoseltamab/>, <https://onco.cc/drugs/belantamab-mafodotin/>, <https://onco.cc/drugs/iberdomide/>, <https://onco.cc/drugs/mezigdomide/>, <https://onco.cc/drugs/arlocabtagene-autoleucel/>, <https://onco.cc/trials/immagine-1/>, <https://onco.cc/trials/quintessential-2/>, <https://onco.cc/ideas/idea-bio1-adaptive-car-antigen-switch/> ;
  onco:standardOfCare <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/isatuximab/>, <https://onco.cc/drugs/carfilzomib/>, <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/belantamab-mafodotin/>, <https://onco.cc/trials/dreamm-7/>, <https://onco.cc/trials/dreamm-8/>, <https://onco.cc/drugs/ciltacabtagene-autoleucel/>, <https://onco.cc/trials/cartitude-4/>, <https://onco.cc/drugs/ciltacabtagene-autoleucel/>, <https://onco.cc/drugs/idecabtagene-vicleucel/>, <https://onco.cc/trials/karmma-3/>, <https://onco.cc/trials/cartitude-1/>, <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/drugs/elranatamab/>, <https://onco.cc/drugs/linvoseltamab/>, <https://onco.cc/trials/majestec-1/>, <https://onco.cc/trials/majestec-3/>, <https://onco.cc/trials/linker-mm1/>, <https://onco.cc/trials/magnetismm-3/>, <https://onco.cc/drugs/talquetamab/>, <https://onco.cc/trials/monumental-1/>, <https://onco.cc/drugs/selinexor/>, <https://onco.cc/drugs/iberdomide/>, <https://onco.cc/drugs/mezigdomide/>, <https://onco.cc/pairings/bcma-then-gprc5d/>, <https://onco.cc/terms/step-up-dosing/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/pairings/bispecific-infection-prophylaxis/> .